The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they …
The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
Already a subscriber? Log in